GO:0102067 geranylgeranyl diphosphate reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0102067 describes the enzymatic activity that reduces geranylgeranyl diphosphate to phytyl diphosphate using NADPH, and also converts geranylgeranyl-chlorophyll a to phytyl-chlorophyll a.
• This activity sits at the intersection of the mevalonate/isoprenoid pathway and chlorophyll biosynthesis, linking geranylgeranyl pyrophosphate (GGPP) pools to phytol production.
• GGPP, the substrate of this reaction, is a critical branch-point metabolite that supports protein geranylgeranylation and adaptive stress responses in cancer cells.
• Mevalonate pathway flux, which supplies GGPP, is dysregulated in multiple malignancies and is a target of statin-based experimental interventions.
• Genetic susceptibility to atypical femoral fractures and statin-associated neuromyotoxicity highlight the clinical importance of isoprenoid metabolism.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of GO:0102067-related genes in disease and development.
Description
GO:0102067, geranylgeranyl diphosphate reductase activity, is a molecular function that catalyzes the NADPH-dependent reduction of geranylgeranyl diphosphate (GGPP) to phytyl diphosphate, and also the reduction of geranylgeranyl-chlorophyll a to phytyl-chlorophyll a. This reaction is a key late step in the biosynthesis of phytol, the hydrophobic tail of chlorophyll, and it directly consumes GGPP, a central isoprenoid intermediate. Because GGPP is also the substrate for protein geranylgeranylation, the enzyme that carries out GO:0102067 sits at a metabolic crossroads between primary metabolism and regulatory lipid modification. Researchers study this activity to understand how plants, algae, and other organisms allocate isoprenoid precursors between chlorophyll synthesis and other essential pathways. In biomedical contexts, the mevalonate pathway that produces GGPP is frequently upregulated in cancer and is modulated by statins, making the enzymes that consume GGPP relevant to oncology and drug development. Consequently, GO:0102067 is not only a plant biochemistry curiosity but a node connecting isoprenoid flux to human disease models and therapeutic strategies.
geranylgeranyl diphosphate reductase activity At A Glance
| GO ID | GO:0102067 |
|---|---|
| GO term | geranylgeranyl diphosphate reductase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Reduction of geranylgeranyl diphosphate to phytyl diphosphate and of geranylgeranyl-chlorophyll a to phytyl-chlorophyll a |
| Reaction direction | Forward reduction using NADPH as electron donor |
| Substrates | Geranylgeranyl diphosphate; geranylgeranyl-chlorophyll a |
| Products | Phytyl diphosphate; phytyl-chlorophyll a; NADP+; H+ |
| Cofactor | NADPH |
| Pathway context | Isoprenoid/mevalonate pathway and chlorophyll biosynthesis |
What Is GO:0102067?
In plain terms, GO:0102067 is the enzyme activity that turns geranylgeranyl diphosphate into phytyl diphosphate by adding hydrogen atoms from NADPH, while also converting geranylgeranyl-chlorophyll a into phytyl-chlorophyll a. The reaction consumes three molecules of NADPH and releases three protons, and it is classified as an oxidoreductase acting on the isoprenoid backbone. This activity is essential for producing the phytyl tail that anchors chlorophyll molecules in photosynthetic membranes.
Why Is geranylgeranyl diphosphate reductase activity Important in Cell Biology?
GO:0102067 is important because it controls the metabolic fate of geranylgeranyl diphosphate, a central isoprenoid precursor that feeds into both chlorophyll synthesis and protein geranylgeranylation. In cancer biology, GGPP availability supports adaptive stress responses and chemoresistance, so enzymes that consume or produce GGPP can influence therapeutic outcomes. In pharmacology, statins lower mevalonate pathway flux and have been associated with neuromyotoxicity and altered cardiac cytokine expression, underscoring the clinical relevance of isoprenoid balance. In plant science, this activity is required for phytol production and photosynthetic function, making it a target for crop improvement and bioenergy research. Thus, understanding GO:0102067 helps explain how cells partition isoprenoid resources and how disruptions contribute to disease or developmental defects.
• Provides phytyl diphosphate for chlorophyll biosynthesis and photosynthetic membrane assembly.
• Consumes GGPP, thereby competing with protein geranylgeranylation reactions that regulate small GTPases.
• Links mevalonate pathway flux to adaptive stress responses in TP53-mutant acute myeloid leukemia.
• Relevant to statin pharmacology, including statin-associated neuromyotoxicity and cardioprotective cytokine upregulation.
• Implicated in cancer metabolism through mevalonate pathway dysregulation across tumor types.
• May influence bone health, as genetic susceptibility to atypical femoral fractures involves isoprenoid-related pathways.
• Serves as a model for studying enzyme evolution and substrate specificity in oxidoreductases.
• Enables synthetic biology approaches to redirect isoprenoid flux toward high-value terpenoids.
• Provides a mechanistic entry point for understanding reactive biliary cell vulnerability in organotypic models.
• Supports development of CRISPR-based disease models to test causal roles of isoprenoid enzymes.
Molecular Mechanism of geranylgeranyl diphosphate reductase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs its substrate, geranylgeranyl diphosphate, and positions it for chemical modification.
The enzyme binds geranylgeranyl diphosphate (GGPP) in its active site, orienting the isoprenoid chain for sequential reduction. This binding step is thought to involve hydrophobic interactions with the geranylgeranyl moiety and electrostatic interactions with the diphosphate group, although detailed structural data for all homologs remain limited. The same active site can also accommodate geranylgeranyl-chlorophyll a, allowing the enzyme to reduce the chlorophyll-bound substrate.
NADPH-dependent reduction
In simple terms: The enzyme uses NADPH as a source of electrons to add hydrogen atoms to the substrate.
Catalysis proceeds through the transfer of hydride equivalents from three molecules of NADPH to the substrate, resulting in the reduction of three double bonds in the geranylgeranyl chain. This step converts geranylgeranyl diphosphate to phytyl diphosphate, and geranylgeranyl-chlorophyll a to phytyl-chlorophyll a. The reaction releases NADP+ and protons, consistent with an oxidoreductase mechanism.
Product release and metabolic channeling
In simple terms: After the reaction, the product is released and can enter chlorophyll synthesis or other pathways.
Phytyl diphosphate is released and becomes available for esterification to chlorophyllide, a late step in chlorophyll biosynthesis. Because GGPP is also a substrate for protein geranylgeranyltransferases, the activity of this enzyme can influence the pool of GGPP available for geranylgeranylation. This competition between pathways highlights the importance of flux control at this metabolic node.
Cofactor and redox regulation
In simple terms: The enzyme depends on NADPH and may be influenced by the cell's redox state.
NADPH availability directly affects the rate of the reaction, linking GO:0102067 activity to cellular redox metabolism. In photosynthetic organisms, light-driven electron transport can influence NADPH pools, thereby indirectly regulating the enzyme. In non-photosynthetic contexts, mevalonate pathway flux determines GGPP supply, which in turn affects the reaction rate.
Subcellular localization and assembly
In simple terms: The enzyme works in specific cellular compartments, often associated with membranes.
In plants and algae, geranylgeranyl diphosphate reductase activity is associated with chloroplast membranes, where chlorophyll biosynthesis occurs. The enzyme may form part of a larger biosynthetic complex that channels intermediates between enzymes. In heterologous systems, expression of the enzyme can be directed to different compartments to study its function.
Key Genes Involved in GO:0102067 geranylgeranyl diphosphate reductase activity
The following genes and proteins are functionally linked to geranylgeranyl diphosphate reductase activity, either as the enzyme itself, as upstream/downstream pathway components, or as regulators of isoprenoid flux.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GGPS1 | Geranylgeranyl diphosphate synthase; produces GGPP | Upstream of GO:0102067; target for modulating substrate supply |
| GGPS2 | Geranylgeranyl diphosphate synthase isoform | Potential redundancy in GGPP production |
| FDPS | Farnesyl diphosphate synthase; earlier isoprenoid pathway | Mevalonate pathway node affecting GGPP levels |
| HMGCR | Rate-limiting enzyme of mevalonate pathway | Statin target; influences GGPP and GO:0102067 flux |
| MVK | Mevalonate kinase | Mevalonate pathway enzyme; mutations cause mevalonate kinase deficiency |
| PMVK | Phosphomevalonate kinase | Mevalonate pathway enzyme |
| MVD | Mevalonate diphosphate decarboxylase | Mevalonate pathway enzyme |
| IDI1 | Isopentenyl diphosphate isomerase | Provides isopentenyl diphosphate for GGPP synthesis |
| IDI2 | Isopentenyl diphosphate isomerase isoform | Tissue-specific isoprenoid synthesis |
| GGR | Geranylgeranyl diphosphate reductase (GO:0102067) | Directly catalyzes the reaction |
| CHLH | Chlorophyll synthesis subunit | Downstream consumer of phytyl diphosphate |
| POR | Protochlorophyllide oxidoreductase | Chlorophyll biosynthesis |
| RABGGTA | Rab geranylgeranyltransferase subunit | Competes for GGPP; affected by GO:0102067 flux |
| RABGGTB | Rab geranylgeranyltransferase subunit | Protein geranylgeranylation |
| PGGT1B | Protein geranylgeranyltransferase type I subunit | Geranylgeranylation of Rho GTPases |
| FNTA | Farnesyltransferase/geranylgeranyltransferase subunit | Isoprenylation of small GTPases |
| RHO | Rho GTPase | Geranylgeranylated protein; downstream of GGPP |
| RAC1 | Rac1 GTPase | Geranylgeranylated protein; cancer relevance |
How Is geranylgeranyl diphosphate reductase activity Regulated?
GO:0102067 is regulated by the availability of its substrates and cofactors, which are in turn controlled by mevalonate pathway flux and photosynthetic electron transport. HMGCR, the rate-limiting enzyme of the mevalonate pathway, is a major upstream regulator and is inhibited by statins, thereby reducing GGPP supply and potentially limiting GO:0102067 activity. In cancer cells, oncogenic signaling can upregulate mevalonate pathway enzymes to sustain GGPP production, which may indirectly influence the reaction. Additionally, redox status and NADPH/NADP+ ratios modulate the enzyme's catalytic rate. Transcriptional regulation of the gene encoding the enzyme itself has been observed in response to developmental and environmental cues in plants, but detailed mechanisms in human contexts remain to be fully elucidated.
geranylgeranyl diphosphate reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HMGCR | Statin response; cancer metabolism | CRISPR knockout in cancer cell lines |
| GGPS1 | GGPP supply; chemoresistance | Point mutation to alter catalytic activity |
| GGR | Chlorophyll biosynthesis; plant development | Knockout in Arabidopsis or algae |
| RABGGTB | Protein geranylgeranylation; cancer | Knock-in of tagged allele for localization |
| FDPS | Mevalonate pathway disorders | Overexpression in patient-derived cells |
Cancer metabolism and chemoresistance
The mevalonate pathway is frequently upregulated in cancers, and GGPP, the substrate of GO:0102067, supports adaptive stress responses that contribute to chemoresistance in TP53-mutant acute myeloid leukemia. Statins, which lower mevalonate flux, have been studied for their effects on cancer metastasis and autophagy, suggesting that modulating GGPP availability could influence tumor progression. Thus, enzymes like the one catalyzing GO:0102067 may affect cancer cell survival by competing for GGPP.
Statin-associated neuromyotoxicity
Statins can cause neuromyotoxicity, a side effect partly attributed to reduced isoprenoid synthesis, including GGPP. Because GO:0102067 consumes GGPP, its activity could modulate the severity of statin-induced effects by altering GGPP pools. However, direct evidence linking this enzyme to statin side effects in humans is still limited and requires further investigation.
Bone health and atypical femoral fractures
Genetic susceptibility to atypical femoral fractures has been linked to variants in genes involved in isoprenoid metabolism and bone remodeling. Although GO:0102067 has not been directly implicated, the pathway that produces its substrate is relevant to bone biology. Future studies could explore whether altered GO:0102067 activity affects bone quality.
Reactive biliary cells and mevalonate vulnerability
An organotypic model of ductular reaction revealed a mevalonate-dependent vulnerability in reactive biliary cells, highlighting the importance of isoprenoid flux in liver injury responses. Since GO:0102067 is part of isoprenoid metabolism, it may influence the survival of reactive biliary cells under stress. This suggests potential therapeutic avenues targeting mevalonate pathway enzymes in liver disease.
From geranylgeranyl diphosphate reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GO:0102067 enzyme affect chlorophyll synthesis? | CRISPR knockout in photosynthetic organisms |
| Does reduced GO:0102067 activity alter GGPP pools and geranylgeranylation? | Point mutation of catalytic residues in human cell lines |
| Can a tagged version of the enzyme reveal its subcellular localization? | Knock-in of fluorescent tag |
| Does overexpression of the enzyme change isoprenoid flux? | Overexpression in mammalian or plant cells |
| Does the enzyme interact with chlorophyll biosynthesis enzymes? | Knock-in of affinity tags followed by proteomics |
| Can CRISPR library screening identify modifiers of GO:0102067 activity? | Genome-wide knockout library in reporter cells |
How to Study the geranylgeranyl diphosphate reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADPH oxidation assay | Enzyme activity | Kinetic characterization of GO:0102067 |
| LC-MS/MS metabolomics | GGPP, phytyl diphosphate levels | Pathway flux analysis |
| RNA-seq | Transcript levels of pathway genes | CRISPR knockout validation |
| Proteomics | Protein abundance and interactions | Identifying complex components |
| Fluorescence microscopy | Subcellular localization | Tagged enzyme imaging |
| CRISPR library screening | Gene essentiality and modifiers | Discovery of novel regulators |
| Western blot | Protein expression | Overexpression and knockout confirmation |
| qPCR | mRNA expression | Rapid screening of edited clones |
Enzymatic assays
Direct measurement of GO:0102067 activity can be performed using purified enzyme or cell lysates by monitoring NADPH oxidation spectrophotometrically or by detecting phytyl diphosphate formation via mass spectrometry. These assays are essential for validating CRISPR models and testing inhibitors.
Metabolomics and lipidomics
Quantification of GGPP, phytyl diphosphate, and related isoprenoids by LC-MS/MS provides a readout of pathway flux and enzyme activity in cells and tissues. This approach can reveal how genetic perturbations alter metabolite pools.
Transcriptomics and proteomics
RNA-seq and proteomics can assess expression changes in mevalonate pathway genes and downstream targets upon CRISPR editing. These methods help identify compensatory mechanisms and regulatory networks.
Imaging and localization
Fluorescence microscopy of tagged enzyme variants allows visualization of subcellular localization, particularly in chloroplasts or other organelles. Co-localization with chlorophyll biosynthetic enzymes can confirm pathway association.
How CRISPR Can Be Used to Study GO:0102067 geranylgeranyl diphosphate reductase activity
Knockout
CRISPR knockout of the gene encoding GO:0102067 can abolish enzyme activity, leading to accumulation of GGPP and depletion of phytyl diphosphate. Such models are useful for studying the metabolic consequences and for validating inhibitor specificity. In cancer cells, knockout can reveal whether the enzyme is required for growth under stress conditions.
Point Mutation
Introducing point mutations in catalytic residues allows fine-tuning of enzyme activity without completely eliminating the protein. This approach can help distinguish between catalytic and structural roles of the enzyme. Point mutations can also model naturally occurring variants associated with disease.
Knock-in
Knock-in of epitope tags or fluorescent proteins enables visualization and affinity purification of the enzyme. Tagged knock-in models are valuable for studying protein interactions and localization in native contexts. Conditional knock-in can also be used to express the enzyme in specific tissues.
Overexpression
Overexpression of the enzyme can increase flux toward phytyl diphosphate and reduce GGPP availability for geranylgeranylation. This can be used to test whether the enzyme is rate-limiting in specific pathways. Overexpression models are also useful for producing phytyl diphosphate in heterologous systems.
How EDITGENE Supports geranylgeranyl diphosphate reductase activity Research
Researchers studying geranylgeranyl diphosphate reductase activity-related genes often need to determine whether a candidate gene is causally involved in isoprenoid metabolism, chlorophyll biosynthesis, or disease-associated phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to enable such causal studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for geranylgeranyl diphosphate reductase activity research.
Frequently Asked Questions About geranylgeranyl diphosphate reductase activity
What is GO:0102067?
GO:0102067 is the Gene Ontology term for geranylgeranyl diphosphate reductase activity, an enzyme that reduces geranylgeranyl diphosphate to phytyl diphosphate using NADPH.
What reaction does geranylgeranyl diphosphate reductase catalyze?
It catalyzes the reduction of geranylgeranyl diphosphate to phytyl diphosphate and of geranylgeranyl-chlorophyll a to phytyl-chlorophyll a, consuming NADPH and releasing NADP+ and protons.
What genes are involved in geranylgeranyl diphosphate reductase activity?
The gene encoding the enzyme itself, as well as upstream mevalonate pathway genes such as HMGCR, FDPS, and GGPS1, and downstream chlorophyll biosynthesis genes.
Why is geranylgeranyl diphosphate reductase important in cancer?
It consumes GGPP, a metabolite that supports adaptive stress responses and chemoresistance in cancer cells, thereby influencing tumor survival.
How is geranylgeranyl diphosphate reductase activity regulated?
It is regulated by substrate availability, NADPH levels, and mevalonate pathway flux, which can be modulated by statins and oncogenic signaling.
What diseases are associated with geranylgeranyl diphosphate reductase activity?
Diseases linked to isoprenoid metabolism include cancer, statin-associated neuromyotoxicity, atypical femoral fractures, and liver injury responses.
What model systems are used to study GO:0102067?
CRISPR knockout, point mutation, knock-in, and overexpression models in cell lines and organisms, combined with metabolomics and enzymatic assays.
Can statins affect geranylgeranyl diphosphate reductase activity?
Statins inhibit HMGCR and reduce mevalonate pathway flux, which can lower GGPP supply and indirectly affect the enzyme's activity.
What methods measure geranylgeranyl diphosphate reductase activity?
NADPH oxidation assays, LC-MS/MS metabolomics, and reporter systems are commonly used.
How can CRISPR help study geranylgeranyl diphosphate reductase?
CRISPR enables precise knockout, point mutation, knock-in, and overexpression to test causal roles in isoprenoid metabolism and disease.
Conclusion
GO:0102067, geranylgeranyl diphosphate reductase activity, is a critical enzymatic function that links isoprenoid metabolism to chlorophyll biosynthesis and protein geranylgeranylation. Its substrate, GGPP, is a key metabolite in cancer and other diseases, making this activity relevant to both plant biology and human health. Understanding its regulation and function through CRISPR-based models will continue to reveal new insights into metabolic control and therapeutic opportunities.
References
- 1. Jiang X et al.. 2026. USP20-Driven Cholesterol Metabolism Links Inflammatory Signaling to Malignancy and Stromal Coevolution in Pancreatic Cancer.. Cancer Res 86(3):712-729 PMID: 41196022
- 2. Baker SK et al.. 2005. Statin-associated neuromyotoxicity.. Drugs Today (Barc) 41(4):267-93 PMID: 16034491
- 3. Ellacott M et al.. 2024. Is there genetic susceptibility for atypical femoral fractures?. Injury 55(2):111312 PMID: 38199157
- 4. Anfuso B et al.. 2025. An organotypic model of ductular reaction reveals a mevalonate-dependent vulnerability in reactive biliary cells.. Cell Rep 44(12):116681 PMID: 41389211
- 5. Skuli SJ et al.. 2025. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.. Leukemia 39(9):2087-2098 PMID: 40634510
- 6. Pentz R et al.. 2018. Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue.. J Cell Mol Med 22(12):6122-6133 PMID: 30216659
- 7. Bathaie SZ et al.. 2017. Mevalonate Pathway and Human Cancers.. Curr Mol Pharmacol 10(2):77-85 PMID: 26758953
- 8. Zhang J et al.. 2013. Statins, autophagy and cancer metastasis.. Int J Biochem Cell Biol 45(3):745-52 PMID: 23147595
